Arbutus announces ceo, william collier, to retire december 31, 2023

Michael j. mcelhaugh, arbutus co-founder and coo, to serve as interim ceo warminster, pa., nov. 07, 2023 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) (“arbutus” or the “company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis b virus (chbv) infection, today announced that william collier will retire from his position as the company's president and chief executive officer, and as a member of the board of directors, at the end of 2023.
ABUS Ratings Summary
ABUS Quant Ranking